It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Single-cell transcriptomics and spatially-resolved imaging/sequencing technologies have revolutionized biomedical research. However, they suffer from lack of spatial information and a trade-off of resolution and gene coverage, respectively. We propose DOT, a multi-objective optimization framework for transferring cellular features across these data modalities, thus integrating their complementary information. DOT uses genes beyond those common to the data modalities, exploits the local spatial context, transfers spatial features beyond cell-type information, and infers absolute/relative abundance of cell populations at tissue locations. Thus, DOT bridges single-cell transcriptomics data with both high- and low-resolution spatially-resolved data. Moreover, DOT combines practical aspects related to cell composition, heterogeneity, technical effects, and integration of prior knowledge. Our fast implementation based on the Frank-Wolfe algorithm achieves state-of-the-art or improved performance in localizing cell features in high- and low-resolution spatial data and estimating the expression of unmeasured genes in low-coverage spatial data.
Single-cell and spatial omics come with a trade-off between resolution and gene coverage. Here, authors bridge this gap via DOT, a multi-objective optimisation model for localising cell features in high/low-resolution spatial data considering cell composition, heterogeneity, and technical effects.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Heidelberg University & Heidelberg University Hospital, Institute for Computational Biomedicine, Heidelberg, Germany (GRID:grid.7700.0) (ISNI:0000 0001 2190 4373); GlaxoSmithKline, Cellzome GmbH, Heidelberg, Germany (GRID:grid.420105.2) (ISNI:0000 0004 0609 8483)
2 GlaxoSmithKline, Cellzome GmbH, Heidelberg, Germany (GRID:grid.420105.2) (ISNI:0000 0004 0609 8483)
3 Heidelberg University & Heidelberg University Hospital, Institute for Computational Biomedicine, Heidelberg, Germany (GRID:grid.7700.0) (ISNI:0000 0001 2190 4373); Jožef Stefan Institute, Department of Knowledge Technologies, Ljubljana, Slovenia (GRID:grid.445211.7)
4 Heidelberg University & Heidelberg University Hospital, Institute for Computational Biomedicine, Heidelberg, Germany (GRID:grid.7700.0) (ISNI:0000 0001 2190 4373)